Oric Pharmaceuticals
ORIC
80 hedge funds and large institutions have $512M invested in Oric Pharmaceuticals in 2021 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 31 increasing their positions, 22 reducing their positions, and 12 closing their positions.
41% more repeat investments, than reductions
Existing positions increased: 31 | Existing positions reduced: 22
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
8% less first-time investments, than exits
New positions opened: 11 | Existing positions closed: 12
2% less funds holding
Funds holding: 82 → 80 (-2)
4.11% less ownership
Funds ownership: 92.63% → 88.52% (-4.1%)
33% less capital invested
Capital invested by funds: $762M → $512M (-$250M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACH
ArrowMark Colorado Holdings
Denver,
Colorado
|
+$10.1M |
| 2 |
Alkeon Capital Management
New York
|
+$6.7M |
| 3 |
SCM
Suvretta Capital Management
New York
|
+$4.55M |
| 4 |
Victory Capital Management
San Antonio,
Texas
|
+$4.04M |
| 5 |
State Street
Boston,
Massachusetts
|
+$3.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CG
Column Group
San Francisco,
California
|
-$18.7M |
| 2 |
Wells Fargo
San Francisco,
California
|
-$16M |
| 3 |
EMFAT
Emerald Mutual Fund Advisers Trust
Leola,
Pennsylvania
|
-$15.5M |
| 4 |
EA
Emerald Advisers
Leola,
Pennsylvania
|
-$15.2M |
| 5 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
-$15.2M |
ORIC Hedge Fund Activity: Q4 2021 in Review
80 of the 6,518 institutional investors tracked by Wall St. Rank reported a position in Oric Pharmaceuticals (ORIC) for Q4 2021, worth a combined $512M — down 33% from $762M a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of ORIC and 11 opened new positions — a net loss of 1 holder — while 22 trimmed existing stakes and 31 added.
The largest buyer was ArrowMark Colorado Holdings, adding an estimated $10.1M. The largest seller was Column Group, cutting an estimated $18.7M.
- 80 institutional investors held Oric Pharmaceuticals (ORIC) as of Q4 2021, down from 82 in Q3 2021.
- Funds reported $512M of Oric Pharmaceuticals stock for Q4 2021, down 33% quarter-over-quarter.
- 11 funds opened new Oric Pharmaceuticals positions in Q4 2021 and 12 closed out, a net change of -1 holder.
- The largest Oric Pharmaceuticals buyer in Q4 2021 was ArrowMark Colorado Holdings, an estimated $10.1M added.
- The largest Oric Pharmaceuticals seller in Q4 2021 was Column Group, an estimated $18.7M sold.
Based on aggregated 13F filings for Q4 2021.